Keyphrases
Immunogenicity
100%
Adjuvanted
100%
Healthy Adults
100%
Hemagglutination Inhibition
100%
Dosing Schedule
100%
Antigen Dose
100%
H7N9 Vaccine
100%
MF59
100%
H7N9
60%
Immune Response
40%
Titer
40%
No Significant Difference
40%
Third Dose
40%
Two-dose Schedule
40%
Older Adults
20%
Antibody Response
20%
Immunogenic
20%
Influenza A
20%
Virion
20%
Body Mass Index
20%
Older Adult Population
20%
Dose Level
20%
Blinded Trial
20%
Vaccine Dose
20%
Influenza Vaccine
20%
Human Influenza
20%
Logistic Regression Modeling
20%
Lichen Planus
20%
Microneutralization Assay
20%
Second Dose
20%
Immune-related Adverse Events
20%
H7N9 Influenza
20%
Seasonal Influenza Vaccine
20%
Influenza A(H7N9)
20%
Inhibition Response
20%
Immune Age
20%
Pustular Psoriasis
20%
Microneutralization
20%
H7N9 Infection
20%
Immunology and Microbiology
Immunogenicity
100%
Normal Human
100%
Antigen
100%
Influenza A Virus (H7N9)
100%
Drug Dose Regimen
100%
MF59
100%
Hemagglutination Inhibition
83%
Titer
66%
Immune Response
33%
Influenza Vaccine
33%
Influenza
33%
Antibody Response
16%
Virion
16%
Immunity
16%
Body Mass
16%
Lichen Planus
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antigen
100%
Immunogenicity
100%
Normal Human
100%
Influenza A Virus (H7N9)
100%
MF59
100%
Influenza Vaccine
40%
Adverse Event
20%
Infection
20%
Influenza A
20%
Seasonal Influenza
20%
Influenza A (H7N9)
20%
Lichen Planus
20%
Guttate Psoriasis
20%